A new clinical trial is set to compare the efficacy and safety of a novel medical device, X92001919, with Paranix Anti-Lice Shampoo, thereby exploring advancements in head lice treatment. This investigation bears significance for healthcare providers, regulatory teams, and medical device professionals tracking innovation in non-invasive treatment modalities.
In this article:
What is the focus of the trial?
The upcoming study, sponsored by Oystershell NV in collaboration with Eurofins Dermscan Pharmascan, seeks to evaluate the performance and safety of X92001919, a physical-mode-action lice treatment device. The trial compares this innovative device to Paranix Anti-Lice Shampoo, a widely used option against headlice infestations.
By adopting a rigorous clinical methodology, this study will address the clinical and regulatory parameters around safety and intended purpose as mandated under international guidelines, including the Medical Device Regulation (MDR) in Europe.
How do the two products compare?
X92001919 is designed with a physical mode of action, distinguishing it from chemical interventions like Paranix Shampoo. The study will analyze critical factors such as:
- Efficacy in removing lice.
- User safety and adverse reactions.
- Ease of application and patient comfort.
Medical devices with physical modes of action offer the potential to reduce exposure to chemical agents, appealing to users with sensitivities or preferences for non-chemical solutions.
When does the study begin?
As of November 2025, the clinical trial is listed as “Not yet recruiting” on the ClinicalTrials.gov database. Healthcare professionals and stakeholders are encouraged to monitor ongoing updates via the official registry.
For additional information about the trial, including future recruitment or results, track the ClinicalTrials.gov record directly.
Frequently Asked Questions
1. What medical conditions does this trial target?
The trial focuses on head lice treatment for patients dealing with lice infestations.
2. What are the study interventions?
The interventions include a device-based treatment (X92001919) and a chemical-based option, Paranix Anti-Lice Shampoo.
3. Who are the sponsors of this study?
The study is sponsored by Oystershell NV, along with Eurofins Dermscan Pharmascan.
Conclusion
This trial offers an opportunity to compare traditional treatment options with a cutting-edge medical device leveraging a physical mode of action. The outcomes may not only impact clinical guidelines but also inform product registrations and market clearances. Interested professionals should closely monitor developments in this trial to stay informed on evolving head lice treatment strategies.
Disclaimer
This publication is intended for professionals and stakeholders in the medical device and regulatory sectors. It does not constitute legal or clinical advice and should not substitute professional judgments.
Announcement Line
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07244523?term=medical+device